Trials / Enrolling By Invitation
Enrolling By InvitationNCT02306720
Registry of Patients With Hypophosphatasia
An Observational, Longitudinal, Prospective, Long-Term Registry Of Patients With Hypophosphatasia (HPP)
- Status
- Enrolling By Invitation
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,571 (estimated)
- Sponsor
- Alexion Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
In this prospective, observational, long term registry patients of all ages with a diagnosis of hypophosphatasia (HPP) are followed at participating sites in multiple countries.
Detailed description
The HPP Registry is an observational, prospective, long-term registry designed to collect data on HPP epidemiology, disease history, clinical course, symptoms and burden of disease from patients of all ages who have a diagnosis of HPP. Evaluation of safety and effectiveness data in patients with HPP who have/are receiving treatment with Asfotase alfa
Conditions
Timeline
- Start date
- 2015-01-20
- Primary completion
- 2031-12-31
- Completion
- 2031-12-31
- First posted
- 2014-12-03
- Last updated
- 2026-02-27
Locations
64 sites across 11 countries: United States, Australia, Austria, Canada, France, Germany, Italy, Poland, Saudi Arabia, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT02306720. Inclusion in this directory is not an endorsement.